Purchase Molnupiravir capsules or tablets online

How and where to order Lagevrio (Molnupiravir) 200 mg pills online:

Shop: MEDS FOR SALE - 5% discount coupon 5OFF
Sellers: MOLNUPIRAVIR STORES
Prices: from $1.94 per pill
Forms: Molnupiravir 200 mg tablets or capsules
Quantity: 1-5 packs of 40 pills
Type: Movfor brand, Lagevrio generic
Payment: Visa, Mastercard, AmEx, Cryptocurrencies
Delivery: Registered airmail, international delivery service
Shipping: Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Lagevrio (Molnupiravir) is an antiviral medicine used to treat mild to moderate COVID-19 (caused by SARS-CoV-2) in adults who are at risk for developing severe illness.

This medication may help people with COVID-19 stay out of the hospital and feel better.


Dosage and administration:

800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days, with or without food.

Take molnupiravir as soon as possible after a diagnosis of COVID-19 has been made, and within 5 days of symptom onset.

Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2.

Molnupiravir is not authorized for use for longer than 5 consecutive days because the safety and efficacy have not been established.


Dosage forms and strengths:

Lagevrio (Molnupiravir) 200 mg capsules for oral use.


Contraindications:

No contraindications of molnupiravir have been identified based on the limited available data on the emergency use of molnupiravir authorized under this emergency use authorization.


Warnings and precautions:

Embryo-fetal toxicity: molnupiravir is not recommended for use during pregnancy.

Hypersensitivity reactions, including anaphylaxis have been reported with molnupiravir. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue this drug.

Bone and cartilage toxicity: molnupiravir is not authorized for use in patients less than 18 years of age because it may affect bone and cartilage growth.


Overdosage:

There is no human experience of overdosage with molnupiravir. Treatment of overdose with molnupiravir should consist of general supportive measures including the monitoring of the clinical status of the patient. Hemodialysis is not expected to result in effective elimination of NHC (N4-hydroxycytidine).


Adverse reactions, side effects:

Most common adverse reactions of molnupiravir (incidence >= 1%) are diarrhea, nausea, and dizziness.

To report suspected adverse reactions of Lagevrio (Molnupiravir) 200 mg capsules, contact Merck pharmaceutical company or your local FDA.


Drug interactions:

No drug interactions with molnupiravir have been identified based on the limited available data on the emergency use of molnupiravir authorized under this emergency use authorization.

No clinical drug-drug interaction trials of molnupiravir with concomitant medications, including other treatments for mild-to-moderate COVID-19, have been conducted.


Use in specific populations:

Pregnancy

The use of molnupiravir is not recommended during pregnancy. Advise individuals of childbearing potential to use effective contraception correctly and consistently, as applicable, for the duration of treatment and for 4 days after the last dose of molnupiravir.

Lactation

Breastfeeding is not recommended during treatment and for 4 days after the last dose of this medicine. A lactating individual may consider interrupting breastfeeding and may consider pumping and discarding breast milk during treatment and for 4 days after the last dose of molnupiravir (Lagevrio).

Pediatric use

Lagevrio is not authorized for use in patients less than 18 years of age. Bone and cartilage toxicity were observed in a 3-month, repeat-dose toxicology study in rats. The safety and efficacy of molnupiravir have not been established in pediatric patients.

Geriatric use

In MOVe-OUT, there was no difference in safety and tolerability between patients >= 65 years of age and younger patients who were treated with molnupiravir. No dosage adjustment is recommended based on age. The PK of NHC was similar in geriatric patients compared to younger patients.

Renal impairment

No dosage adjustment in patients with any degree of renal impairment is recommended. Renal clearance is not a meaningful route of elimination for NHC. Mild or moderate renal impairment did not have a meaningful impact on the PK of NHC. While the PK of NHC has not been evaluated in patients with eGFR less than 30 mL/min/1.73m 2 or on dialysis, severe renal impairment, and end-stage renal disease (ESRD) are not expected to have a significant effect on NHC exposure.

Hepatic impairment

No dosage adjustment of molnupiravir in patients with hepatic impairment is recommended. Preclinical data indicate that hepatic elimination is not expected to be a major route of NHC elimination therefore, hepatic impairment is unlikely to affect NHC exposure.


Patient counseling information:

Hypersensitivity reactions

Inform patients that hypersensitivity reactions have been reported, even following a single dose of molnupiravir (Lagevrio) capsules or tablets, and to discontinue the drug and to inform their healthcare provider at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (for example, swelling of the lips, tongue, face, tightness of the throat, hoarseness), or other symptoms of an allergic reaction.

Risk of fetal toxicity

Advise patients that molnupiravir is not recommended for use in pregnancy because it may cause fetal harm. Advise individuals of childbearing potential to inform their healthcare provider of a known or suspected pregnancy.

Advise individuals of childbearing potential to use effective contraception correctly and consistently while taking molnupiravir and for 4 days after the last dose.

While the risk is regarded as low, nonclinical studies to fully assess the potential for molnupiravir to affect offspring of treated males have not been completed. Advise sexually active individuals with partners of childbearing potential to use a reliable method of contraception consistently and correctly while taking molnupiravir and for at least 3 months after the last dose of this medication. The risk beyond 3 months after the last dose of molnupiravir is unknown. Studies to understand the risk beyond three months are ongoing.

Risk of bone and cartilage toxicity

Lagevrio (Molnupiravir) is not authorized for use in patients less than 18 year of age as it may affect bone growth and cartilage formation.

Pregnancy surveillance program

There is a pregnancy surveillance program that monitors pregnancy outcomes in individuals exposed to molnupiravir during pregnancy. Encourage participation and advise patients about how they may enroll in the pregnancy surveillance program. Advise patients who have taken molnupiravir during pregnancy to report their pregnancy to Merck Sharp & Dohme Corp.

Lactation

Breastfeeding is not recommended while taking molnupiravir and for 4 days after the last dose of molnupiravir. Advise lactating individuals to consider interrupting breastfeeding and to consider pumping and discarding breast milk during treatment and for 4 days after the last dose of molnupiravir.

Administration instructions

Inform patients to take molnupiravir (Lagevrio) pills with or without food. Advise patients to swallow molnupiravir capsules whole, and to not open, break, or crush the capsules. Instruct patients that if they miss a dose of molnupiravir and it is within 10 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 10 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. Advise the patient to not double the dose to make up for a missed dose.

Alert the patient of the importance of completing the full 5-day treatment course and to continuing isolation in accordance with public health recommendations to maximize viral clearance and minimize transmission of SARS-CoV-2.